Conditions: Ischemic Stroke Excitotoxicity Memantine
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 47
Healthy volunteers: no

Brief summary:
The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.

Detailed description:

Arms:
arm 1: Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days. arm 2: Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.

Interventions: intervention 1: Placebo intervention 2: Memantine
Intervention descriptions: intervention 1: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks. intervention 2: Beside the usual treatment for ischemic stroke this group will be treated by memantine.

Protocol document: